Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017

Alcohol, cigarette smoking predict mortality in head and neck cancer

24 Sep 2017

Overall survival (OS) and head and neck cancer (HNC)-specific survival vary among HNC sites, according to a study. In particular, cigarette smoking is a prognostic factor of OS and HNC-specific survival in patients with cancer of the oral cavity and oropharynx, whereas alcohol consumption is a prognostic factor of both survival outcomes in patients with cancer of the larynx.

Pooled analysis involving 4,759 HNC patients from five studies within the International Head and Neck Cancer Epidemiology Consortium showed that 5-year OS was 51.4 percent for all HNC sites combined. Individually, the rates were 50.3 percent for oral cavity, 41.1 percent for oropharynx, 35 percent for hypopharynx and 63.9 percent for larynx.

In terms of HNC-specific survival, 5-year survival rates were 57.4 percent for all HNC combined, with 54.6 percent for oral cavity, 45.4 percent for oropharynx, 37.1 percent for hypopharynx and 72.3 percent for larynx.

Older age at diagnosis and advanced tumour staging were found to be unfavourable predictors of OS and HNC-specific survival. In laryngeal cancer specifically, low educational level was a negative prognostic factor for OS (high school or lower vs college graduate: hazard ratio [HR], 2.54; 95 percent CI, 1.01 to 6.38), and status and intensity of alcohol drinking for both the OS (current drinkers: HR, 1.73; 1.16 to 2.58) and HNC-specific survival (current drinkers: HR, 2.11; 1.22 to 3.66).

In oropharyngeal cancer, on the other hand, smoking status was an independent unfavourable prognostic factor for OS. Smoking intensity (>20 cigarettes/day: HR, 1.41; 1.03 to 1.92) was also a negative predictor of OS in patients with cancer of the oral cavity.

More studies that involve a large sample of patients and allow the adjustment for the main confounders, including comorbidities, and the lifestyle habits after the diagnosis are needed to define and highlight the differences of HNC subsites in terms of lifestyle-related prognostic factors, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
22 Jan 2018
In a symposium chaired by Dr Yoon-Sim Yap of the National Cancer Centre Singapore, renowned regional and international experts in the field of breast cancer, Dr Yen-Shen Lu from Taiwan and Professor Nadia Harbeck from Germany, joined her in providing insights on the current treatment landscape of hormone receptor-positive (HR+) advanced breast cancer. In their respective sessions, they each highlighted new therapeutic options including the optimal use of dual blockade therapy for oestrogenreceptor-positive (ER+) advanced breast cancer for patients in Asia. 
Pearl Toh, 19 Dec 2016
Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), showed significantly greater efficacy than platinum-pemetrexed therapy in advanced non-small cell lung cancer (NSCLC) patients positive for T790M mutation, including those with central nervous system (CNS) metastases, according to data from the AURA3* trial.
Dr Joslyn Ngu, 23 Nov 2017
Highlights from the Joint Cancer Genetics Meeting and the 15th International Meeting on the Psychosocial Aspects of Hereditary Cancer (IMPAHC) 2017